Preclinical evidence for the role of stem/stromal cells in COPD
Bölükbas, Deniz LU ; Augusto Silva, Iran LU
; Rydell-Törmänen, Kristina
LU
and Wagner, Darcy
LU
(2019)
p.73-96
- Abstract
- Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide and there are currently limited treatment options for these patients. The disease is characterized by a reduction in airflow due to chronic bronchitis, as well as airspace enlargement in the distal lung, resulting in a loss of surface area available for gas exchange. At end-stage disease, oxygen therapy and lung transplantation remain the only potential options. The disease is heterogeneous and both inflammatory cells as well as structural cells are thought to play a role in disease onset and progression. Pharmaceutical approaches are ineffective at reversing disease pathology and currently aim only to provide symptomatic relief. A recent area of... (More)
- Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide and there are currently limited treatment options for these patients. The disease is characterized by a reduction in airflow due to chronic bronchitis, as well as airspace enlargement in the distal lung, resulting in a loss of surface area available for gas exchange. At end-stage disease, oxygen therapy and lung transplantation remain the only potential options. The disease is heterogeneous and both inflammatory cells as well as structural cells are thought to play a role in disease onset and progression. Pharmaceutical approaches are ineffective at reversing disease pathology and currently aim only to provide symptomatic relief. A recent area of investigation focuses on exogenous cell therapy, including stem cell administration, and its potential for directing lung regeneration. Cell therapies from a variety of sources, as well as cell-derived products such as extracellular vesicles, have recently shown efficacy in animal models of COPD, but early clinical trials have not yet shown efficacy. In this chapter, we discuss the different animal models of COPD as well as the studies which have been conducted to date with cell therapies. We conclude the chapter with a discussion regarding the limitations of current animal models and discuss potential areas for future study. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/8e881791-a4b2-4937-a6c4-951d0776bae0
- author
- Bölükbas, Deniz
LU
; Augusto Silva, Iran
LU
; Rydell-Törmänen, Kristina
LU
and Wagner, Darcy
LU
- organization
- publishing date
- 2019
- type
- Chapter in Book/Report/Conference proceeding
- publication status
- published
- subject
- keywords
- Cell therapy, Chronic bronchitis, COPD, Emphysema, Lung regeneration, Stem cells
- host publication
- Stem Cell-Based Therapy for Lung Disease
- editor
- Burgess, Janette K and Heijink, Irene H.
- edition
- 1
- pages
- 24 pages
- publisher
- Springer International Publishing
- external identifiers
-
- scopus:85085817385
- ISBN
- 9783030294021
- 9783030294038
- DOI
- 10.1007/978-3-030-29403-8_5
- language
- English
- LU publication?
- yes
- id
- 8e881791-a4b2-4937-a6c4-951d0776bae0
- date added to LUP
- 2019-12-03 14:28:07
- date last changed
- 2024-01-16 16:26:14
@inbook{8e881791-a4b2-4937-a6c4-951d0776bae0,
abstract = {{Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death worldwide and there are currently limited treatment options for these patients. The disease is characterized by a reduction in airflow due to chronic bronchitis, as well as airspace enlargement in the distal lung, resulting in a loss of surface area available for gas exchange. At end-stage disease, oxygen therapy and lung transplantation remain the only potential options. The disease is heterogeneous and both inflammatory cells as well as structural cells are thought to play a role in disease onset and progression. Pharmaceutical approaches are ineffective at reversing disease pathology and currently aim only to provide symptomatic relief. A recent area of investigation focuses on exogenous cell therapy, including stem cell administration, and its potential for directing lung regeneration. Cell therapies from a variety of sources, as well as cell-derived products such as extracellular vesicles, have recently shown efficacy in animal models of COPD, but early clinical trials have not yet shown efficacy. In this chapter, we discuss the different animal models of COPD as well as the studies which have been conducted to date with cell therapies. We conclude the chapter with a discussion regarding the limitations of current animal models and discuss potential areas for future study.}},
author = {{Bölükbas, Deniz and Augusto Silva, Iran and Rydell-Törmänen, Kristina and Wagner, Darcy}},
booktitle = {{Stem Cell-Based Therapy for Lung Disease}},
editor = {{Burgess, Janette K and Heijink, Irene H.}},
isbn = {{9783030294021}},
keywords = {{Cell therapy; Chronic bronchitis; COPD; Emphysema; Lung regeneration; Stem cells}},
language = {{eng}},
pages = {{73--96}},
publisher = {{Springer International Publishing}},
title = {{Preclinical evidence for the role of stem/stromal cells in COPD}},
url = {{http://dx.doi.org/10.1007/978-3-030-29403-8_5}},
doi = {{10.1007/978-3-030-29403-8_5}},
year = {{2019}},
}